Target Gene/Pathway Pathway / Gene
Search results
| No. | KEGG PATHWAY On map, Yellow: Drug target, Red: All disease-related | KEGG GENES | KEGG DRUG | DrugBank | Disease ID |
|---|---|---|---|---|---|
| 1 | Allograft rejection 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Depemokimab Depemokimab 💬
| Depemokimab | 044 [2] 44, 45 💬
|
| 2 | Allograft rejection 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Mepolizumab Mepolizumab 💬
| Mepolizumab | 044 [4] 44, 45, 98, 162 💬
|
| 3 | Allograft rejection 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Reslizumab Reslizumab 💬
| Reslizumab | 044 [2] 44, 98 💬
|
| 4 | Asthma 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Depemokimab Depemokimab 💬
| Depemokimab | 044 [2] 44, 45 💬
|
| 5 | Asthma 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Mepolizumab Mepolizumab 💬
| Mepolizumab | 044 [4] 44, 45, 98, 162 💬
|
| 6 | Asthma 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Reslizumab Reslizumab 💬
| Reslizumab | 044 [2] 44, 98 💬
|
| 7 | Autoimmune thyroid disease 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Depemokimab Depemokimab 💬
| Depemokimab | 044 [2] 44, 45 💬
|
| 8 | Autoimmune thyroid disease 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Mepolizumab Mepolizumab 💬
| Mepolizumab | 044 [4] 44, 45, 98, 162 💬
|
| 9 | Autoimmune thyroid disease 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Reslizumab Reslizumab 💬
| Reslizumab | 044 [2] 44, 98 💬
|
| 10 | Cytokine-cytokine receptor interaction 💬 2 genes, 4 drugs (DrugBank) and 5 diseases |
IL5 [1] IL5 💬
|
Depemokimab Depemokimab 💬
| Depemokimab | 044 [2] 44, 45 💬
|
| 11 | Cytokine-cytokine receptor interaction 💬 2 genes, 4 drugs (DrugBank) and 5 diseases |
IL5 [1] IL5 💬
|
Mepolizumab Mepolizumab 💬
| Mepolizumab | 044 [4] 44, 45, 98, 162 💬
|
| 12 | Cytokine-cytokine receptor interaction 💬 2 genes, 4 drugs (DrugBank) and 5 diseases |
IL5 [1] IL5 💬
|
Reslizumab Reslizumab 💬
| Reslizumab | 044 [2] 44, 98 💬
|
| 13 | Cytokine-cytokine receptor interaction 💬 2 genes, 4 drugs (DrugBank) and 5 diseases |
IL5RA [1] IL5RA 💬
|
Benralizumab Benralizumab 💬
| Benralizumab | 044 [5] 44, 45, 98, 162, 299 💬
|
| 14 | Fc epsilon RI signaling pathway 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Depemokimab Depemokimab 💬
| Depemokimab | 044 [2] 44, 45 💬
|
| 15 | Fc epsilon RI signaling pathway 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Mepolizumab Mepolizumab 💬
| Mepolizumab | 044 [4] 44, 45, 98, 162 💬
|
| 16 | Fc epsilon RI signaling pathway 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Reslizumab Reslizumab 💬
| Reslizumab | 044 [2] 44, 98 💬
|
| 17 | Hematopoietic cell lineage 💬 2 genes, 4 drugs (DrugBank) and 5 diseases |
IL5 [1] IL5 💬
|
Depemokimab Depemokimab 💬
| Depemokimab | 044 [2] 44, 45 💬
|
| 18 | Hematopoietic cell lineage 💬 2 genes, 4 drugs (DrugBank) and 5 diseases |
IL5 [1] IL5 💬
|
Mepolizumab Mepolizumab 💬
| Mepolizumab | 044 [4] 44, 45, 98, 162 💬
|
| 19 | Hematopoietic cell lineage 💬 2 genes, 4 drugs (DrugBank) and 5 diseases |
IL5 [1] IL5 💬
|
Reslizumab Reslizumab 💬
| Reslizumab | 044 [2] 44, 98 💬
|
| 20 | Hematopoietic cell lineage 💬 2 genes, 4 drugs (DrugBank) and 5 diseases |
IL5RA [1] IL5RA 💬
|
Benralizumab Benralizumab 💬
| Benralizumab | 044 [5] 44, 45, 98, 162, 299 💬
|
| 21 | IL-17 signaling pathway 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Depemokimab Depemokimab 💬
| Depemokimab | 044 [2] 44, 45 💬
|
| 22 | IL-17 signaling pathway 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Mepolizumab Mepolizumab 💬
| Mepolizumab | 044 [4] 44, 45, 98, 162 💬
|
| 23 | IL-17 signaling pathway 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Reslizumab Reslizumab 💬
| Reslizumab | 044 [2] 44, 98 💬
|
| 24 | Inflammatory bowel disease 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Depemokimab Depemokimab 💬
| Depemokimab | 044 [2] 44, 45 💬
|
| 25 | Inflammatory bowel disease 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Mepolizumab Mepolizumab 💬
| Mepolizumab | 044 [4] 44, 45, 98, 162 💬
|
| 26 | Inflammatory bowel disease 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Reslizumab Reslizumab 💬
| Reslizumab | 044 [2] 44, 98 💬
|
| 27 | Intestinal immune network for IgA production 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Depemokimab Depemokimab 💬
| Depemokimab | 044 [2] 44, 45 💬
|
| 28 | Intestinal immune network for IgA production 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Mepolizumab Mepolizumab 💬
| Mepolizumab | 044 [4] 44, 45, 98, 162 💬
|
| 29 | Intestinal immune network for IgA production 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Reslizumab Reslizumab 💬
| Reslizumab | 044 [2] 44, 98 💬
|
| 30 | JAK-STAT signaling pathway 💬 2 genes, 4 drugs (DrugBank) and 5 diseases |
IL5 [1] IL5 💬
|
Depemokimab Depemokimab 💬
| Depemokimab | 044 [2] 44, 45 💬
|
| 31 | JAK-STAT signaling pathway 💬 2 genes, 4 drugs (DrugBank) and 5 diseases |
IL5 [1] IL5 💬
|
Mepolizumab Mepolizumab 💬
| Mepolizumab | 044 [4] 44, 45, 98, 162 💬
|
| 32 | JAK-STAT signaling pathway 💬 2 genes, 4 drugs (DrugBank) and 5 diseases |
IL5 [1] IL5 💬
|
Reslizumab Reslizumab 💬
| Reslizumab | 044 [2] 44, 98 💬
|
| 33 | JAK-STAT signaling pathway 💬 2 genes, 4 drugs (DrugBank) and 5 diseases |
IL5RA [1] IL5RA 💬
|
Benralizumab Benralizumab 💬
| Benralizumab | 044 [5] 44, 45, 98, 162, 299 💬
|
| 34 | Pathways in cancer 💬 2 genes, 4 drugs (DrugBank) and 5 diseases |
IL5 [1] IL5 💬
|
Depemokimab Depemokimab 💬
| Depemokimab | 044 [2] 44, 45 💬
|
| 35 | Pathways in cancer 💬 2 genes, 4 drugs (DrugBank) and 5 diseases |
IL5 [1] IL5 💬
|
Mepolizumab Mepolizumab 💬
| Mepolizumab | 044 [4] 44, 45, 98, 162 💬
|
| 36 | Pathways in cancer 💬 2 genes, 4 drugs (DrugBank) and 5 diseases |
IL5 [1] IL5 💬
|
Reslizumab Reslizumab 💬
| Reslizumab | 044 [2] 44, 98 💬
|
| 37 | Pathways in cancer 💬 2 genes, 4 drugs (DrugBank) and 5 diseases |
IL5RA [1] IL5RA 💬
|
Benralizumab Benralizumab 💬
| Benralizumab | 044 [5] 44, 45, 98, 162, 299 💬
|
| 38 | T cell receptor signaling pathway 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Depemokimab Depemokimab 💬
| Depemokimab | 044 [2] 44, 45 💬
|
| 39 | T cell receptor signaling pathway 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Mepolizumab Mepolizumab 💬
| Mepolizumab | 044 [4] 44, 45, 98, 162 💬
|
| 40 | T cell receptor signaling pathway 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Reslizumab Reslizumab 💬
| Reslizumab | 044 [2] 44, 98 💬
|
| 41 | Th1 and Th2 cell differentiation 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Depemokimab Depemokimab 💬
| Depemokimab | 044 [2] 44, 45 💬
|
| 42 | Th1 and Th2 cell differentiation 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Mepolizumab Mepolizumab 💬
| Mepolizumab | 044 [4] 44, 45, 98, 162 💬
|
| 43 | Th1 and Th2 cell differentiation 💬 1 gene, 3 drugs (DrugBank) and 4 diseases |
IL5 [1] IL5 💬
|
Reslizumab Reslizumab 💬
| Reslizumab | 044 [2] 44, 98 💬
|
